Posted by
Adjunctive Riluzole Shows Promise in Treatment-Resistant Depression

Adjunctive Riluzole Shows Promise in Treatment-Resistant Depression

The glutamate blocker riluzole may have longer-term beneficial effects as adjunctive treatment for some patients with treatment-resistant depression, according to results of a trial published in the Journal of Affective Disorders. The US Food and Drug Administration approved riluzole for the treatment of amyotrophic lateral sclerosis in 1994. It inhibits presynaptic release of glutamate and acts directly […]

Posted by
Antidepressant Adherence Linked to Increased Survival in Patients With Cancer, Study Finds

Antidepressant Adherence Linked to Increased Survival in Patients With Cancer, Study Finds

A study published this week in Depression & Anxiety suggests that among patients with cancer who are prescribed antidepressants, those who take the medication may live longer than those who are non-adherent. Patients with cancer are known to have higher rates of depression than the general public—a factor that may reduce adherence to cancer treatment and increase their […]

Posted by
How Pharmacogenomics Can Help Patients with Treatment-Resistant Depression

How Pharmacogenomics Can Help Patients with Treatment-Resistant Depression

Treatment-resistant depression can be a frustrating challenge for doctor and patient alike. The trial-and-error process of trying different medications and treatments to see what alleviates patients’ depression symptoms can feel like a “shot in the dark” approach. According to Ann McDonald, former editor of the Harvard Mental Health Letter, in her blog post on the Harvard […]

Posted by
Mild Depression Predictive of All-Cause Mortality After MI

Mild Depression Predictive of All-Cause Mortality After MI

Mild depression was a long-term independent predictor of death in patients after acute myocardial infarction (AMI), per cohort study data published in Heart, Lung and Circulation. Investigators conducted a 25-year follow-up of men who were recruited after AMI to participate in a randomized controlled trial in the 1980s. The initial trial investigated the impact of high intensity exercise […]

Posted by
The Psychopharmacology of Depression: Strategies, Formulations, and Future Implications

The Psychopharmacology of Depression: Strategies, Formulations, and Future Implications

With well over two dozen traditional antidepressants available in the US, and an ever-growing list of other psychotropic compounds with apparent antidepressant properties, pharmacological options for treating clinical depression today are broad and vast. However, recent findings suggest that the magnitude of efficacy for most antidepressants compared with placebo may be more modest than previously […]

Posted by
“Brain Zaps” Reported by Some Following Antidepressant Discontinuation

“Brain Zaps” Reported by Some Following Antidepressant Discontinuation

Abrupt discontinuation of an antidepressant was found to be the most likely cause of brain zaps A recently published article discusses the characteristics, symptoms, and effects on quality of life associated with brain zaps, the electrical phenomenon that can occur following antidepressant discontinuation. The study authors explained, “In some patients, stopping or reducing the dose of an […]

Posted by
TMS for Perinatal Depression

TMS for Perinatal Depression

By Paul Croarkin, DO, Research Committee Co-chair and Philip Janicak, MD, Research Committee Member Introduction Perinatal depressions are serious, debilitating conditions which are often under-recognized; and, even when properly diagnosed, often sub-optimally treated.  Notably, they can contribute to problematic maternal behaviors such as substance use, poor self-care, non-adherence to prenatal care, and a heightened risk for […]

Posted by

WITHOUT REMISSION, THE BURDEN OF MDD GROWS

For 50 years, pharmacological treatment approaches in MDD have focused on targeting monoamine receptors in the hopes of reducing symptoms. While conventional therapies have helped many, the STAR*D trial* revealed that as many as a third of patients may not achieve remission despite treatment with traditional antidepressants.¹,² Dr Rakesh Jain, clinical professor of psychiatry at […]

Posted by
Brexanolone Infusion Rapidly Relieves Postpartum Depression

Brexanolone Infusion Rapidly Relieves Postpartum Depression

NEW YORK (Reuters Health) – A 60-hour infusion of brexanolone significantly improves symptoms in women with postpartum depression, according to results from two phase 3 trials. The results “confirm and extend the previous work showing that brexanolone has a rapid onset of action that is unlike anything else currently available,” said Dr. Samantha Meltzer-Brody from […]

Posted by
A Deeper Understanding of Major Depressive Disorder is Within Reach

A Deeper Understanding of Major Depressive Disorder is Within Reach

WHY AREN’T SOME PATIENTS WITH MDD REACHING REMISSION? For more than 50 years, major depressive disorder (MDD) pharmacological treatment approaches have focused on increasing the level of monoamine neurotransmitters in the brain, with the hope of reducing symptoms.1 And while conventional antidepressants have helped most, the STAR*D trial* found that one-third of patients didn’t achieve remission after multiple treatment […]